Stocks and Investing Stocks and Investing
Mon, March 11, 2024

Josh Schimmer Maintained (BBIO) at Buy with Increased Target to $60 on, Mar 11th, 2024


Published on 2024-10-28 09:36:09 - WOPRAI, Josh Schimmer
  Print publication without navigation


Josh Schimmer of Cantor Fitzgerald, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $50 to $60 on, Mar 11th, 2024.

Josh has made no other calls on BBIO in the last 4 months.



There are 4 other peers that have a rating on BBIO. Out of the 4 peers that are also analyzing BBIO, 1 agrees with Josh's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024


These are the ratings of the 3 analyists that currently disagree with Josh


  • Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $53 on, Tuesday, March 5th, 2024
  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $47 on, Monday, March 4th, 2024
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024
Contributing Sources